Emmanuel Ekanem

Emmanuel Ekanem

Auto-generated profile, based on publicly available information

Emmanuel Ekanem

Inova Fairfax Hospital, Falls Church, VA, USA

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 July 2024 in Nature Medicine
Verified
Journal Article
Open access
PDF file
EEEmmanuel Ekanem
Emmanuel Ekanem
PNPetr Neuzil
Petr Neuzil
TRTobias Reichlin
Tobias Reichlin
JKJoseph Kautzner
Joseph Kautzner
PVPepijn van der Voort
Pepijn van der Voort
VRVivek Y. Reddy
Vivek Y. Reddy
Pulsed field ablation (PFA) is an emerging technology for the treatment of atrial fibrillation (AF), for which pre-clinical and early-stage clinical data are suggestive of some degree of preferentiality to myocardial tissue ablation without damage to adjacent structures. Here in the MANIFEST-17K study we assessed the safety of PFA by studying the post-approval use of this treatment modality. Of the 116 centers performing post-approval PFA with a pentaspline catheter, data were received from 106 centers (91.4% participation) regarding 17,642 patients undergoing PFA (mean age 64, 34.7% female, 57.8% paroxysmal AF and 35.2% persistent AF). No esophageal complications, pulmonary vein stenosis or persistent phrenic palsy was reported (transient palsy was reported in 0.06% of patients; 11 of 17,642). Major complications, reported for ~1% of patients (173 of 17,642), were pericardial tamponade (0.36%; 63 of 17,642) and vascular events (0.30%; 53 of 17,642). Stroke was rare (0.12%; 22 of 17,642) and death was even rarer (0.03%; 5 of 17,642). Unexpected complications of PFA were coronary arterial spasm in 0.14% of patients (25 of 17,642) and hemolysis-related acute renal failure necessitating hemodialysis in 0.03% of patients (5 of 17,642). Taken together, these data indicate that PFA demonstrates a favorable safety profile by avoiding much of the collateral damage seen with conventional thermal ablation. PFA has the potential to be transformative for the management of patients with AF.

1 June 2022 in EP Europace
Verified
Journal Article
Open access
PDF file
EEEmmanuel Ekanem
Emmanuel Ekanem
VRVivek Y Reddy
Vivek Y Reddy
BSBoris Schmidt
Boris Schmidt
TRTobias Reichlin
Tobias Reichlin
KNKars Neven
Kars Neven
MCMANIFEST-PF Cooperative
MANIFEST-PF Cooperative
Pulsed field ablation (PFA) is a novel atrial fibrillation (AF) ablation modality that has demonstrated preferential tissue ablation, including no oesophageal damage, in first-in-human clinical trials. In the MANIFEST-PF survey, we investigated the ‘real world’ performance of the only approved PFA catheter, including acute effectiveness and safety—in particular, rare oesophageal effects and other unforeseen PFA-related complications. This retrospective survey included all 24 clinical centres using the pentaspline PFA catheter after regulatory approval. Institution-level data were obtained on patient characteristics, procedure parameters, acute efficacy, and adverse events. With an average of 73 patients treated per centre (range 7–291), full cohort included 1758 patients: mean age 61.6 years (range 19–92), female 34%, first-time ablation 94%, paroxysmal/persistent AF 58/35%. Most procedures employed deep sedation without intubation (82.1%), and 15.1% were discharged same day. Pulmonary vein isolation (PVI) was successful in 99.9% (range 98.9–100%). Procedure time was 65 min (38–215). There were no oesophageal complications or phrenic nerve injuries persisting past hospital discharge. Major complications (1.6%) were pericardial tamponade (0.97%) and stroke (0.4%); one stroke resulted in death (0.06%). Minor complications (3.9%) were primarily vascular (3.3%), but also included transient phrenic nerve paresis (0.46%), and TIA (0.11%). Rare complications included coronary artery spasm, haemoptysis, and dry cough persistent for 6 weeks (0.06% each). In a large cohort of unselected patients, PFA was efficacious for PVI, and expressed a safety profile consistent with preferential tissue ablation. However, the frequency of ‘generic’ catheter complications (tamponade, stroke) underscores the need for improvement.

17 January 2025 in EP Europace
Verified
Journal Article
Open access
USUniv.-Prof. Priv.-Doz. Dr.med.univ. Daniel Scherr
Univ.-Prof. Priv.-Doz. Dr.med.univ. Daniel Scherr
MTMohit K Turagam
Mohit K Turagam
PMPhilippe Maury
Philippe Maury
YBYuri Blaauw
Yuri Blaauw
PVPepijn van der Voort
Pepijn van der Voort
VRVivek Y Reddy
Vivek Y Reddy
Aims: Initial clinical studies of pulsed field ablation (PFA) to treat atrial fibrillation (AF) indicated a >90% durability rate of pulmonary vein isolation (PVI). However, these studies were largely conducted in single centres and involved a limited number of operators. We aimed to describe the electrophysiological findings and outcomes in patients undergoing repeat ablation after an initial PF ablation for AF. Methods and results: In the MANIFEST-REDO study, we investigated patients who underwent repeat ablation due to clinical recurrence—AF or atrial tachycardia (AT)—following first-ever PVI with a pentaspline PFA catheter (Farawave, Boston Scientific Inc.). At 22 centres, 427 patients (age 64 ± 11 years; 37% female) were included. Of note, the recurrent arrhythmia leading to the repeat ablation was paroxysmal AF (51%), persistent AF (30%), or AT (19%). At the repeat procedure, the PV reconnection rates were 30% (left superior pulmonary vein), 28% (left inferior pulmonary vein), 33% (right superior pulmonary vein), and 32% (right inferior pulmonary vein). In 45% of patients, all PVs were durably isolated at the beginning of the repeat procedure, with the previous use of any imaging or mapping modality being univariately associated with durable PVI. After a post-redo follow-up period of 284 (90–366) days, the primary effectiveness endpoint (freedom from documented AF/AT lasting ≥30 s after 3-month blanking without class I/III antiarrhythmic drugs or symptoms) was achieved in 65% of patients, with significant differences between groups (PAF 65% vs. PersAF 56% vs. AT 76%; P = 0.04). Persistent AF as recurrent arrhythmia after the initial PFA ablation predicted AT/AF recurrence after repeat ablation [hazard ratio 1.241 (95% confidence interval 1.534–1.005); P = 0.045]. The procedural complication rate was 2.8%. Conclusion: In repeat procedures for AF/AT performed after an index procedure with PFA for AF, PV reconnections are not uncommon. Repeat procedures can be performed safely and with an acceptable subsequent success rate.

1 August 2020 in CASE
Verified
Journal Article
Open access
EEEmmanuel Ekanem
Emmanuel Ekanem
RGRaghav Gattani
Raghav Gattani
JSJennifer Shea
Jennifer Shea
QZQiong Zhao
Qiong Zhao
RSRamesh Singh
Ramesh Singh
RLRyan P. Liam
Ryan P. Liam
• Inversion of the LAA is very rare and is associated with negative intracardiac pressure. • High LVAD speeds induce negative intracardiac pressure and can cause LAA inversion. • LAA inversion can lead to mitral valve outflow obstruction and RV failure. • This has the potential to be a catastrophic complication after LVAD implantation.

1 February 2021 in JACC: Case Reports
Verified
Journal Article
Open access
AMAndrei Minciunescu
Andrei Minciunescu
EEEmmanuel Ekanem
Emmanuel Ekanem
BNBradley Nitta
Bradley Nitta
FCFelix Castro
Felix Castro
HDHussain Dhanani
Hussain Dhanani
A 21-year-old man presented with new-onset seizures and brain abscess. Echocardiography and cardiac magnetic resonance imaging revealed underlying Ebstein anomaly, secundum atrial septal defect, and cor triatriatum dexter. The elevated right heart pressures shunting through the septal defect and transient bacteremia were the likely mechanisms for his presentation. (Level of Difficulty: Intermediate.)

1 March 2020 in JACC
Verified
Journal Article
Closed access
RGRaghav Gattani
Raghav Gattani
EEEmmanuel Ekanem
Emmanuel Ekanem
JSJennifer Shea
Jennifer Shea
QZQiong Zhao
Qiong Zhao
RSRamesh Singh
Ramesh Singh
RLRyan P. Liam
Ryan P. Liam